TABLE 1.
Key baseline characteristics, follow‐up, and number of patients with kidney events for the four SGLT2 inhibitor cardiovascular outcome trials identified for the meta analysis
| EMPA‐REG OUTCOME8, 13, 14 | CANVAS Program6, 15 | DECLARE‐TIMI 587, 16 | VERTIS CV2, 5 | |
|---|---|---|---|---|
| Number of patients | 7020 | 10 142 | 17 160 | 8246 |
| Mean age (years) | 63 | 63 | 64 | 64 |
| Female (%) | 29 | 36 | 37 | 30 |
| Caucasian (%) | 72 | 78 | 80 | 88 |
| ASCVD (%) | 100 | 66 | 41 | 100 |
| Mean HbA1c (%) | 8.1 | 8.2 | 8.3 | 8.2 |
| Mean BMI (kg/m2) | 31 | 32 | 32 | 32 |
| Mean SBP (mmHg) | 135 | 137 | 135 | 133 |
| Mean eGFR (ml/min/1.73 m) | 74 | 77 | 85 | 76 |
| Mean duration of follow‐up (years) | NA | 3.6 | NA | 3.5 |
| Median duration of follow‐up (years) | 3.1 | 2.4 | 4.2 | 3.0 |
| Number of patients with composite kidney events (n) | 186 | 249 | 365 | 198 |
| Sustained 40% decline in eGFR (n) | 175 | 239 | 341 | 192 |
| Kidney replacement therapy (n) | 25 | 18 | 25 | 12 |
| Kidney death (n) | NA | 3 | 16 | 2 |
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; SBP, systolic blood pressure.